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Abstract
High glucose production contributes to fed and fasted hyperglycemia in Type 1 Diabetes (T1D)
and Type 2 Diabetes (T2D). The breakdown of the adiponectin signaling pathway in T1D and the
reduction of circulating adiponectin in T2D contribute to this abnormal increase in glucose
production. Sufficient amounts of insulin could compensate for the loss of adiponectin signaling in
T1D and T2D and reduce hyperglycemia. However, the combination of low adiponectin signaling
and high insulin resembles an insulin resistance state associated with cardiovascular disease and
decreased life expectancy. Future development of medications that correct the deficiency of
adiponectin signaling in the liver could restore the metabolic balance in T1D and T2D and reduce
the need for insulin. This article reviews the adiponectin signaling pathway in the liver through T-
cadherin, AdipoR1, AdipoR2, AMPK, ceramidase activity, APPL1 and the recently discovered
Suppressor Of Glucose from Autophagy (SOGA).
1. Liver contribution to circulating glucose
The liver releases glucose ensuring sufficient amounts of this essential fuel are always
available in the circulation for other tissues. Endocrine and neural mechanisms stimulate the
liver during fasting, exercise and pregnancy to meet the increased demand for glucose. In
addition to ensuring the availability of glucose, the liver plays a major role in preventing
hyperglycemia. Hyperglycemia causes increased osmolarity, oxidative damage, glycation
end products and other changes that contribute to the life threatening complications of
diabetes. Liver glucose production is lowered through (a) the inhibition of gluconeogenesis,
glycogenolysis, proteolysis and lipolysis and (b) the stimulation of glycolysis and the
synthesis of glycogen, protein and lipids.
2. Adiponectin suppression of liver glucose production
Adiponectin (30 kDa) is a hormone produced by adipocytes that was discovered in 1995 by
subtractive hybridization studies aimed at identifying adipocyte differentiation genes [1].
The idea that adipocytes secrete an insulin sensitizing protein was inconceivable before the
reduction of adiponectin mRNA in the obese state was reported in 1996 [2]. Computed
tomography (CT) scans that showed omental fat expansion is associated with the reduction
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of circulating adiponectin in 1999 suggested that adiponectin could raise liver insulin
sensitivity [3].
Human adiponectin consists of 244 amino acids that generate a collagenous N-terminal
domain and a globular C-terminal domain [4]. About 90% of the circulating adiponectin in
humans is bound in (a) a high molecular weight (HMW) structure (360–540 kDa)
comprised of either 12 or 18 adiponectin molecules or (b) a low molecular weight (LMW)
structure (180 kDa) comprised of 6 adiponectin molecules. At 5 μg/ml, the molar
concentration of HMW and LMW adiponectin in human plasma is approximately 3 nM [5].
The remaining 10% of the circulating adiponectin in humans is bound in a structure (90
kDa) called the full-length adiponectin trimer comprised of 3 adiponectin molecules.
HMW, LMW adiponectin and full-length trimers are stable in solution, meaning that a
decrease in one isoform does not enable the remaining isoforms to restore the balance [6].
However, under reducing conditions (low pH) that result in disulfide bond cleavage in vitro,
HMW and LMW adiponectin produce full-length trimers and globular domain trimers that
lack the collagenous N-terminal domain [1, 7, 8]. The reduction and proteolytic processing
of HMW and LMW adiponectin is reviewed below in the context of receptor binding.
Intraperitoneal injection of HMW and LMW adiponectin lowers plasma glucose in healthy
mice as well as mice with Type 1 Diabetes (T1D) and Type 2 Diabetes (T2D) [9]. High
doses of adiponectin do not cause hypoglycemia. Insulin lowers plasma glucose by lowering
glucose production and raising glucose disposal. Insulin injection does not cause
hypoglycemia when its ability to stimulate glucose uptake is eliminated [10]. The absence of
hypoglycemia in mice injected with high doses of HMW and LMW adiponectin suggests the
glucose lowering effect of adiponectin is primarily mediated through the inhibition of
glucose production.
Euglycemic clamp studies using tracers could distinguish whether the reduction of plasma
glucose is mediated by a decrease in glucose production, an increase in glucose disposal or
both. Intravenous infusion of HMW and LMW adiponectin in mice, causing a 3-fold
elevation in circulating adiponectin, lowers glucose production by 65% without any effect
on glucose disposal or glycolysis [11]. Targeted genetic modifications in mice, causing a 3-
fold elevation or a complete absence of HMW and LMW adiponectin, have effects solely on
glucose production as well [12–14].
Cultured liver cells release glucose into the media, but short exposure to HMW and LMW
adiponectin inhibits glucose production by 20–40% [9, 15]. Similar exposure to full-length
adiponectin trimers, derived by disulfide bond cleavage of HMW and LMW adiponectin,
lowers glucose production by 90% [8].
3. Clinical Correlation: Low adiponectin and Type 2 Diabetes
Low circulating adiponectin in the obese and lipodystrophic states can cause an elevation in
glucose production that causes an increase in beta cell insulin secretion [16, 17]. Frank
diabetes can be avoided as long as the beta cell could compensate for the reduction of
circulating adiponectin. However, when the beta cell cannot keep glucose production under
Combs and Marliss Page 2






















control, the decrease in circulating adiponectin could raise glucose production, contributing
to the appearance of T2D.
Interest in the therapeutic properties of adiponectin peaked amid reports that a class of
highly effective oral diabetes medications cause a 2- to 3-fold elevation in circulating
adiponectin [18]. Thiazolinedione (TZD) drugs are amphipathic compounds that interact
with the ligand binding domain of peroxisome proliferator-activated receptor-gamma
(PPAR-γ), a member of the steroid receptor family of transcription factors and dominant
promoter of adipocyte differentiation. Studies in T2D patients, adiponectin transgenic and
knockout mice suggest the therapeutic effects of TZD drugs are at least partly mediated by
the elevation of adiponectin followed by decreases in liver glucose production, circulating
glucose and insulin [8, 12, 13, 18].
TZD drugs restore circulating levels of adiponectin in people with T2D, sparing the beta cell
from having to overproduce insulin and reducing the unwanted effects of hyperinsulinemia
[19]. When prescribed alone, TZDs lower glucose without the risk of hypoglycemia;
however, concerns about their side effects have shifted the focus on adiponectin-based
therapeutics away from the elevation of circulating adiponectin [20]. The sheer abundance
of circulating adiponectin, its complex structures and short half-life (150 minutes) make the
activation of the adiponectin signaling pathway a more promising target in the clinical
treatment of T2D than the elevation of circulating adiponectin [21].
4. Liver cell surface receptors
The reduction of Cys-Cys bonds and proteolytic processing of HMW and LMW adiponectin
into full-length and globular adiponectin trimers suggests that circulating adiponectin
mediates its effects through a cell surface receptor system that depends on multiple proteins.
Accordingly, three cell surface receptors were identified between 2003 and 2004. HMW and
LMW adiponectin ligands led to the identification of T-cadherin whereas full-length and
globular adiponectin trimers led to the identification of adiponectin receptor-1 and -2
(AdipoR1 and AdipoR2) (Figure 1).
Adiponectin binding to T-cadherin (90 kDa) is evident using N-Flag-tagged HMW and
LMW murine adiponectin, anti-Flag linked magnetic beads, retroviral transduced murine
bone marrow Ba/F3 cells expressing a murine C2C12 myoblast undifferentiated cDNA
library and, finally, PCR amplification of isolated clones. T-cadherin-adiponectin binding is
also evident by co-immunoprecipitation, ELISA and FACS based binding assays [22]. The
half-maximal binding concentration of HMW and LMW adiponectin to stable transfected C-
GFP-tagged T-cadherin in Chinese hamster ovary (CHO) cells is 25 nM (trimer
equivalents). T-cadherin does not bind to full-length adiponectin trimers or globular
adiponectin trimers.
T-cadherin was discovered in the nervous system, but it has widespread tissue distribution
including the liver [23]. It belongs to a family of cell surface proteins involved in Ca2+
mediated cell-cell interactions [24]. The globular domain of adiponectin contains a Ca2+
binding site, dependent on Asp 288, that plays a role in T-cadherin binding [6]. Ca2+
chelators like EDTA block T-cadherin binding in Ba/F3 cells suggesting a potential role of a
Combs and Marliss Page 3






















divalent cation such as Ca2+ in hormone-receptor interactions [22]. T-cadherin gene ablation
produces a 10-fold elevation in circulating adiponectin due to the release of adiponectin that
is normally sequestered to the cell surface [25].
T-cadherin is not an integral membrane protein. It is retained on the extracellular membrane
by a glycosylphosphatidylinositol (GPI) anchor that localizes to caveolin-rich microdomains
called lipid rafts [26]. The mechanism of T-cadherin mediated signaling may be similar to
other GPI-anchored signal-transducing receptors capable of recruiting additional proteins
upon ligand binding. The absence of an intracellular domain, the lipid raft link and the
absence of full-length or globular adiponectin trimer binding to T-cadherin suggest the
adiponectin signaling pathway depends on additional co-receptors.
Adiponectin binding to AdipoR1 (42 kDa) is evident using fluorescent labeled globular
adiponectin trimers, retroviral transduced Ba/F3 cells expressing a human skeletal muscle
cDNA library and clone selection by fluorescence-activated cell sorting (FACS) [27].
AdipoR1-globular adiponectin trimer binding is also evident by yeast two-hybrid screening
of human fetal brain cDNA [28].
AdipoR1 has 7 transmembrane domains, like G-protein coupled receptors, but an inverse
topology [27]. Yeast two-hybrid screening shows that the globular adiponectin trimer
interacts with C-terminal domain of AdipoR1 (aa 311–375) [28]. AdipoR1 is not a tyrosine
kinase receptor like the insulin receptor. In vivo labeling studies reveal little tyrosine
phosphorylation of AdipoR1 under basal or adiponectin-stimulated conditions [28].
AdipoR2 (34 kDa), identified on the basis of its homology to AdipoR1, is highly liver
specific [27]. Full-length adiponectin trimer has a higher binding affinity to liver membrane
fractions than globular adiponectin trimers [29]. In C2C12 myocytes, the globular
adiponectin trimer binds with greater affinity to AdipoR1 (Kd = 1.14 nM) than AdipoR2 (Kd
= 14.4 nM). Scatchard plot analysis shows siRNA mediated suppression of AdipoR1
decreases globular adiponectin trimer binding without affecting full-length adiponectin
trimer binding and vice versa. T-cadherin, AdipoR1 and AdipoR2 do not bind to C1q, a
structural homologue of adiponectin that attaches to immunoglobulin for complement
fixation [22, 27].
5. A shield against lipotoxicity
Adiponectin is not an “insulin mimetic” (Figure 2). Increasing circulating levels of insulin to
compensate for the loss of adiponectin signaling in T1D and T2D promotes lipid storage
which causes an even greater need for insulin. The detrimental effects of high insulin and
low adiponectin signaling in humans can be seen in fatty liver and cardiovascular disease
[19, 30]. The development of therapies that restore adiponectin signaling in T1D and T2D
provides a way to avoid lipotoxicity.
Adiponectin lowers intracellular lipid content by two mechanisms. Adiponectin inhibition of
liver glucose production lowers circulating levels of insulin which decreases insulin
mediated lipogenesis and insulin mediated inhibition of fatty acid (FA) oxidation (Figure 2).
Adiponectin also stimulates FA oxidation directly. The half-maximal doses for FA oxidation
Combs and Marliss Page 4






















through AdipoR1 and AdipoR2 in C2C12 myocytes are 0.5 nM and 6 nM, respectively [27].
Studies in mice and human hepatoma (HepG2) cells suggest that adiponectin does not affect
liver triacylglycerol (TAG) secretion [31].
Acute exposure to HMW and LMW adiponectin activates AMP-activated kinase (AMPK)
in rat hepatoma McArdle 7777 cells [32]. AMPK is a serine/threonine kinase that inhibits
acetyl CoA carboxylase (ACC), a rate limiting enzyme in de novo lipogenesis [33]. AMPK
suppression of ACC lowers malonyl-CoA production thereby increasing the oxidation of
long chain FAs and circumventing insulin mediated lipid synthesis (Figure 3). Adiponectin
activates AMPK through two independent pathways involving liver kinase B1 (LKB1) and
Ca2+/calmodulin-dependent protein kinase kinase (CaMKK).
LKB1 is a serine/threonine protein kinase that activates AMPK upon translocating to the
cytosol. Adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper
containing 1 (APPL1) is a 100 kDa endosomal protein expressed in mouse hepatocytes and
other cells that binds to the N-terminal domains of AdipoR1 and AdipoR2 [34]. Yeast two-
hybrid screens using a human fetal brain cDNA library show the phosphotyrosine binding
(PTB) domain on the C-terminal end of APPL1 (aa 455–693) interacts with the intracellular
N-terminal domains of AdipoR1 (aa 4–136) and AdipoR2 (aa 4–142) [28]. APPL1:APPL1
homodimerization is required for AdipoR1 and AdipoR2 binding [35]. In muscle,
adiponectin signaling is suppressed by APPL2, an APPL1 homologue that forms an
APPL1:APPL2 heterodimer. As such, increased APPL2 expression blocks receptor binding.
CaMKK is an alternate upstream kinase of AMPK that shares significant sequence and
structural homology with LKB1 [36]. Both purified HMW adiponectin and recombinant
globular adiponectin trimers activate CaMKK [37–39]. AdipoR1 mediated Ca2+ release in
C2C12 myotubes activates CaMKK [38, 39]. Intracellular Ca2+ release involves
phospholipase C (PLC) production of inositol triphosphate (IP3). Adiponectin receptor
mediated activation of PLC is independent of APPL1, but may involve G-proteins used by
GPCRs. Besides APPL1, other proteins can bind to the intracellular domain of AdipoR1,
including endoplasmic reticulum protein 46 (ERp46), activated protein kinase C1 (RACK1)
and protein kinase CK2β subunit (CK2β) [40].
Adiponectin does not stimulate FA oxidation by increasing intracellular AMP
concentrations or diacylglycerol (DAG) levels in the plasma membrane. While causing a
transient change in adenosine nucleotide levels, the energy status is rapidly restored by the
rise in FA oxidation and the drop in lipogenesis and gluconeogenesis, a process referred to
as substrate switching [41]. Adrenergic hormones also stimulate lipolysis and FA oxidation.
However, adiponectin does not affect membrane DAG content, a second messenger in G-
protein coupled receptor signaling and activator of protein kinase C (PKC), in hepatocytes
and liver samples from leptin deficient (ob/ob) or high fat diet (HFD) induced obese mice.
6. Adiponectin mediated ceramidase activity
In addition to the accumulation of intracellular lipid droplets, lipotoxicity can be linked to
the abundance of specific lipids. Ceramides are bioactive sphingolipids produced by the
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liver that interfere with insulin signaling. Insulin activation of phosphatidylinositol-3 kinase
(PI3K) causes a transient increase of phosphatidylinositol-3,4,5-phosphate (PIP3) in cell
membranes that binds to Akt, also known as protein kinase B (PKB). Ceramide activation of
PKCζ interferes with PIP3 binding to Akt/PKB in L6 muscle cells [42]. Ceramide also
impairs insulin signaling by PP2A and PKC epsilon (PKCε) activation in human embryonic
kidney 293 cells (HEK 293) and cancer cells [43, 44]. In contrast, the metabolism of
ceramides into phosphorylated sphingoid bases, such as sphingosine-1-phosphate (S1P),
reduces insulin resistance [45–47].
Adiponectin lowers liver ceramide content [48, 49]. In agreement with euglycemic clamp
results in other mice, adiponectin infusion in ob/ob mice lowers liver ceramide content and
glucose production concurrently [11–14]. Notably, it has no effect on glucose disposal.
Adiponectin decreases all ceramide and dihydroceramide species regardless of saturation or
acyl chain length [14]. It stimulates deacylation of ceramides at neutral pH in a dose-
dependent manner producing sphingosine, S1P and dihydrosphingosine-1-phosphate.
AdipoR1 and AdipoR2 belong to the family of progesterone/adiponectin/adipoQ receptors
(PAQR) that stimulate intracellular ceramidase activity [50]. Both contain a series of
histidine residues that are conserved among ceramidases. Substituting these histidines for
arginines lowers the ceramidase activity of AdipoR1 and AdipoR2 [14]. Adenoviral vectors
that double liver AdipoR1 and AdipoR2 expression increase ceramidase activity, lowering
the ceramide content of the liver while improving insulin sensitivity in HFD-induced insulin
resistant mice [14].
Mouse embryonic fibroblasts (MEFs) derived from fetal livers cannot produce glucose, but
they demonstrate the synergy between T-cadherin, AdipoR1 and AdipoR2. HMW and LMW
adiponectin triggered increases in ceramidase activity are blocked in AdipoR1/AdipoR2 −/−
(double-knockout) MEFs [14]. Adiponectin mediated increases in ceramidase activity may
lower hepatic glucose production by altering the lipid composition of the plasma membrane.
The ceramide content of lipid rafts is higher in AdipoR1 and AdipoR2 deficient MEFs [14].
Catabolic conditions stimulate liver glucose production by cell autonomous mechanisms
retained in tissue culture. Nutrient deficient media induce a marked increase in hepatocyte
glucose production before triggering apoptosis. However, the addition of HMW and LMW
adiponectin increases MEF survival [14]. S1P, a potent stimulator of cell growth, rescues
AdipoR1 and AdipoR2 deficient MEFs from cell death [45, 51]. Despite its antiapoptotic
effects, adiponectin is associated with tumor suppression in the liver and other tissues [23,
52].
7. Suppression of gluconeogenic enzymes
Tracer studies using deuterated water show that adiponectin lowers glucose production in rat
hepatoma (McArdle 7777) cells by suppressing both glycogenolysis and gluconeogenesis
[32]. Suppression of glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate carboxy
kinase (PEPCK) inhibits glycogenolysis and gluconeogenesis. HMW, LMW and full-length
adiponectin trimer lower liver G6Pase and PEPCK mRNA expression in lab rodents [11, 29,
53–55].
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Adiponectin inhibition of glucose production can be blocked by (a) the expression of a
dominant negative AMPK mutant in hepatoma cells and (b) gene ablation of AMPK in mice
[29, 32, 56]. How is it possible for AMPK to exert such a dominant effect on plasma glucose
when the reduction of intracellular lipids by itself is insufficient in the clinical treatment of
diabetes [18]? The answer is that, in addition to inhibiting ACC and decreasing intracellular
lipid stores, AMPK lowers liver G6Pase and PEPCK mRNA expression.
Gluconeogenic hormones such as glucagon stimulate G6Pase and PEPCK mRNA
expression by activating the cAMP-responsive element-binding (CREB) (Figure 4). CREB
stimulation of G6Pase and PEPCK mRNA expression depends on binding to the CREB-
regulated transcription coactivator (CRTC2), also called transducer of regulated cAMP
response element–binding protein 2 (TORC2), which drives the expression of PPARγ
cofactor-1 alpha (PGC1α). PGC1α binds to the nuclear hormone receptors hepatic nuclear
factor-4 α (HNF4α) and the forkhead family member Foxo1 driving G6Pase and PEPCK
mRNA expression [57]. Adenoviral small hairpin RNA (shRNA) for TORC2 lowers
glucagon-stimulated PGC-1α expression [58]. Glucagon stimulation dephosphorylates
TORC2 allowing TORC2 translocation to the nucleus where it enhances CREB-dependent
transcription of PGC1α, G6Pase and PEPCK mRNA expression.
Adiponectin activation of AMPK blocks G6Pase and PEPCK mRNA expression by
promoting TORC2 phosphorylation and blocking its translocation to the nucleus (Figure 4).
Liver specific knockout of LKB1 through adenovirus bearing CMV-Cre causes TORC2
dephorphorylation and increased PGC1α, PEPCK and G6Pase mRNA expression [58, 59].
AMPK mediated induction of the immediate early transcription factor Early Growth
Response 1 (EGR1) and Dual Specificity Phosphatase (DUSP4) also lowers G6Pase and
PEPCK expression and glucose production in Fao rat hepatoma cell lines [60]. Other
relevant AMPK targets in hepatocytes include glycogen synthase, insulin response substrate
1 and -2 (IRS-1 and IRS-2) [61–63].
Adiponectin mediated suppression of G6Pase and PEPCK mRNA expression in mouse
hepatocytes may also occur independently of LKB1, AMPK and TORC2 (Figure 4).
Adiponectin mediated decreases in glucogenic gene expression, hepatic glucose production
and plasma glucose is partly preserved after liver LKB1 deletion by viral expression of CRE
recombinase [54]. LKB1 and AMPK null hepatocytes exhibit a lack of correlation between
TORC2 electrophoretic mobility and adiponectin suppression of PEPCK and G6Pase
expression. Adiponectin and AMPK do not suppress glucagon and cAMP induced PKA
phosphorylation of target proteins. However, hepatocytes from TORC2-null mice
demonstrate robust adiponectin-induced repression of PGC1α, a target gene of protein
kinase A (PKA).
Adiponectin mediated decreases in G6Pase and PEPCK expression can be triggered
independent of AMPK through convergence of the adiponectin and insulin signaling
pathways through APPL1. Insulin lowers PEPCK and G6Pase expression through PI3K
(Figure 4) [64]. PI3K production of PIP3 promotes Akt/PKB translocation to the nucleus
wherein Akt/PKB phosphorylates Foxo1, a member of the Forkhead/winged helix family of
transcription factors [65]. Tribble-3 (TRB3) prevents Akt/PKB translocation to the plasma
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membrane. [66, 67]. APPL1 interferes with TRB3 binding increasing insulin-stimulated
Akt/PKB phosphorylation [68]. APPL1 reduces Akt/PKB-TRB3 binding in the liver of
leptin receptor deficient (db/db) mice. APPL1 overexpression also increases the
phosphorylation of mitogen-activated protein kinase (p38 MAPK) in mouse hepatocytes,
but it does not affect every aspect of insulin signaling. APPL1 does not affect insulin
stimulated MAP kinase (p42/44 Erk) phosphorylation.
NFκB can also inhibit glucose production by stimulating the production of nitric oxide NO
(Figure 4) [69]. Adiponectin stimulation of APPL1 prevents obesity-induced vascular
insulin resistance and endothelial dysfunction by modulating the endothelial production of
nitric oxide (NO) [70]. In C2C12 myocytes, adiponectin phosphorylates IκB which activates
NFκB, a heterodimer of two DNA-binding subunits, p50 and p65 [71]. IκB retains NFκB in
the cytoplasm under basal conditions. IκB phosphorylation allows the translocation of
NFκB to the nucleus where it can regulate gene expression. However, NFκB also increases
NO production in hepatocytes by stimulating inducible NO synthase (iNOS) expression
[72]. NFκB inhibits glucocorticoid and glucagon induction of glucose production [73].
TLR4, IL1-R and TNFα–R suppress the gene expression of G6Pase and PEPCK through
NFκB [74, 75]. Adiponectin activation of NFκB in macrophages occurs independent of
AdipoR1 and AdipoR2 [63]. NFκB targeting must be hepatocyte specific as the liver’s
resident macrophages, Kupffer cells, could elicit an innate immune response [76].
8. Suppression of gluconeogenic substrate availability
Besides the regulation of rate limiting enzymes, such as G6Pase and PEPCK, glucose
production can be suppressed by decreasing the availability of energy, reducing equivalents
and substrates [77–79]. Adiponectin stimulation of FA oxidation generates energy and
reducing equivalents making the reduction of substrate availability a potential target for the
inhibition of glucose production (Figure 5).
The hydrolysis of peptide bonds through proteasomal and autophagic mechanisms is
associated with the presumed elevation of gluconeogenic amino acid availability and the
appearance of hyperglycemia [80, 81]. Food withdrawal, streptozotocin induced diabetes,
glucagon, epinephrine and glucocorticoids increase autophagy in the liver [82–85].
Adiponectin mediated increases in ceramidase activity may contribute to an inhibition of
autophagy; however, the possibility that adiponectin lowers autophagy through AMPK is
ruled out as AMPK stimulation of Ulk1 and AMPK inhibition of the mammalian target of
rapamycin (mTOR) increase autophagy [86–88].
The search for an inhibitor of autophagy in the adiponectin signaling pathway led to the
discovery of a previously unknown protein called the Suppressor of Glucose from
Autophagy (SOGA) (Figure 5) [89]. Proteomic analysis shows that HMW and LMW
adiponectin upregulate SOGA in hepatoma and hepatocyte cultures. siRNA knockdown of
SOGA stimulates autophagy and proteolysis in hepatocytes blocking adiponectin inhibition
of glucose production. AICAR, an AMP analogue that stimulates AMPK and
glycogenolysis, lowers SOGA in primary hepatocytes [90, 91]. LY294002, which blocks the
ATP binding site in PI3K, also lowers SOGA [92].
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The elevation of protein turnover suggests that substrate availability is linked to the increase
in gluconeogenesis and glucose production in T2D [93, 94]. As such, the loss of adiponectin
signaling could lower SOGA in the liver and muscle contributing to the appearance of
hyperglycemia. Proteolytic cleavage of SOGA yields a C-terminal fragment that is secreted
into the extracellular space and further processed in the circulation (Figure 6) [89]. The
circulating SOGA fragment provides a surrogate marker for changes in the intracellular
levels of SOGA. TZD treatment and calorie restriction, interventions that increase
circulating adiponectin and restore glucose homeostasis, raise SOGA and lower glucose in
ob/ob and wild-type mice.
9. Clinical Correlation: Low Adiponectin Signaling and Type 1 Diabetes
The marked increase of circulating adiponectin with little benefit in people with T1D
indicates a breakdown of the adiponectin signaling pathway [95]. In nonobese diabetic
(NOD) mice, an autoimmune model of T1D, the loss of adiponectin signaling in the liver is
evident from the reduction of SOGA [89]. Insulin injection eliminates hyperglycemia in
NOD mice without correcting the deficiency of SOGA. TZD drugs prescribed for the
treatment of insulin resistance in T1D may work by stimulating the production of SOGA
through adiponectin. However, considering the breakdown of the adiponectin signaling
pathway in T1D, the development of medications that stimulate the production of SOGA
directly could restore the metabolic balance, diminish the insulin requirement and improve
clinical outcomes.
10. Restoring the activity of the adiponectin signaling pathway in the liver
Adiponectin is a hormone that slows down the liver’s production of glucose. The loss of
adiponectin signaling in the liver contributes to the elevation of glucose in T1D and T2D.
Insulin does not fully compensate for the loss of adiponectin signaling in T1D and T2D. The
adiponectin signaling pathway within liver cells provides molecular and phenotypic targets
for the development of drugs that can restore the body to the nondiabetic state.
The loss of adiponectin signaling in T1D is due to a breakdown of the adiponectin signaling
pathway. The loss of adiponectin signaling in T2D is due to low circulating adiponectin.
Chronic calorie restriction and TZD drugs raise circulating levels of adiponectin. The
elevation of circulating adiponectin is beneficial in the treatment of T2D, when the
adiponectin signaling pathway is intact. The development of “adiponectin sensitizers”, drugs
that activate the intermediates in the adiponectin signaling pathway directly, is necessary to
restore adiponectin signaling in T1D.
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Figure 1. Synergy Model of Adiponectin Receptors
HMW and LMW adiponectin binding to T-cadherin leads to (a) disulfide bond cleavage
producing “full-length adiponectin trimers” that bind to AdipoR2 and (b) proteolytic
cleavage producing “globular adiponectin trimers” that bind to AdipoR1. T-Cadherin,
AdipoR1 and AdipoR2 expression is not limited to hepatocytes.
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Figure 2. Similarities and Differences between Adiponectin and Insulin Effects in the Liver
Adiponectin and insulin reduce circulating lipids by different mechanisms. Insulin
stimulation of lipogenesis in the liver converts excess glucose into fatty acids that are
incorporated into triglyceride molecules that are packed in lipoprotein particles and secreted.
Adiponectin increases fatty acid and triglyceride clearance by stimulating fatty acid
oxidation in the liver [12].
Combs and Marliss Page 17






















Figure 3. Adiponectin Regulation of Lipid Metabolism
Adiponectin activation of AMPK by Ca2+ dependent and Ca2+ independent pathways,
involving LKB1 and CaMKK, increases FA oxidation decreasing intracellular lipid stores
and insulin resistance.
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Figure 4. Adiponectin Regulation of G6Pase and PEPCK Expression in Hepatocytes in Relation
to Insulin Receptor and Glucagon Receptor Action
The catalytic activity of G6Pase and PEPCK is regulated at the level of gene expression.
Adiponectin regulation of PGC1α and iNOS mRNA can play a role the suppression of
G6Pase and PEPCK mRNA.
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Figure 5. Rate Limiting Enzymes and Biochemical Substrates needed for Liver Glucose
Production via Gluconeogenesis and Glycogenolysis
Liver cell glucose production can be lowered by decreasing the catalytic activity of pyruvate
carboxylase (PCase), PEPCK, fructose-1,6-bisphosphatase (F16PPase) and glucose-6-
phosphatase (G6Pase) and increasing the catalytic activity of pyruvate dehydrogenease
(PDH). Liver cells cannot synthesize or metabolize branched chain amino acids (BCAAs).
Adiponectin upregulation of SOGA inhibits autophagy lowering the availability of
gluconeogenic amino acids for the synthesis of glucose.
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Figure 6. Proteolytic Processing of SOGA and Potential Mechanism of Action
Full-length SOGA contains Atg16 and Rab5-binding motifs, an internal signal peptide (SP)
and a C-terminal species specific antigenic epitope (SSE). Autophagy involves the
encapsulation of protein in membrane bound vacuoles that fuse with lysosomes and the
release of free amino acids. This model shows (a) the proteolytic processing of full-length
SOGA at the internal signal site, (b) the N-terminal fragment of SOGA interfering with the
formation of the Atg12-Atg5-Atg16 complex required for the initiation of autophagy, (c) the
secretion of the C-terminal fragment of SOGA and (d) further processing of the C-terminal
fragment to produce the circulating 25 kDa C-terminal fragment of SOGA.
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